BioStock: Elicera’s first clinical CAR T-Cell study CARMA set to begin

Elicera Therapeutics is on the brink of launching its first clinical CAR T-cell study, CARMA, which aims to generate crucial data for its lead CAR T-cell candidate ELC-301 and the iTANK immune-boosting technology.
– We expect to be able to treat the first patients after summer and thus present interim data from the first dosage group with three patients at the turn of the year 2024/2025, says CEO Jamal El-Mosleh in Elicera’s 2024 Q1 report.

Read the article at biostock.se:

https://www.biostock.se/en/2024/05/eliceras-first-clinical-car-t-cell-study-carma-set-to-begin/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/